The Relationship Between Serum AMH Dynamics and Early or Normal Ovarian Response to Corifollitropin Alfa

NCT ID: NCT04482751

Last Updated: 2023-02-08

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 80 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2020-08-01
• Study Completion Date: 2023-09-30

Brief Summary

The objective of this study is to evaluate the trend of serum AMH during IVF (in vitro fertilization) cycles, in particular the possible relationship between the dynamics of AMH and the early or normal response to therapies for controlled ovarian stimulation with corifollitropin alfa. The secondary objective is to study the association between the number of follicles equal to or greater than 17 mm on the eighth day of ovarian stimulation and the decline in AMH, and to assess the predictability of the need to add additional therapies after the first week of stimulation ovarian.

Detailed Description

The study is observational and it is monocentric, and it will involve 80 patients. Patients' data, extrapolated from the medical records of the Department of Reproductive Medicine in the Policlinico Hospital in Modena, will be collected in an internal database for analysis. The inclusion criteria for the population included in the study will be: 1) basal serum FSH concentration below 20 UI/L; 2) age between 18 and 46 years; 3) body weight > 60 kg; 4) use of corifollitrofin alpha for ovarian stimulation. The following parameters will be evaluated: the age of the patients, their weight, their body mass index (BMI), duration of infertility, cycle characteristics; basal (day 2) AMH, AFC measurement, basal estradiol, basal progesterone, basal FSH, basal LH, and those same values on day 5 and day 8 of ovarian stimulation; follicles ≥ 17 mm on day 8, type of gonadothropin further added, days of stimulation with the further gonadothropin and its units per day, AMH on trigger day and the number of oocytes retrieved. The confidentiality of the informations will be guaranteed by anonymized data analysis. All the data are commonly recorded in our clinical practice.

The observed period will be of 12 months. The date of conclusion of the study, after favorable opinion of the Ethics Committee and the authorization of the Company Management, is scheduled for June 2021.

To guarantee the consent and the information of the patients involved in the study, the Information Sheet and the relative Consent Form are attached. We consider appropriate to inform the General Physician of the enlisted patients about the study: the Information Letter for the General Physician is therefore attached.

Variables/Time Points of Interest

The variables which will be recorded on cycle day 2 of a spontaneous menstruation (stimulation day 1 with Corifollitropin alfa) are: woman's age (years), weight (kg), body-mass-index (kg/m2), duration of infertility (months), cycle length (in days, by patient recall), cycle regularity (yes/no; deviation of > 5 days from two consecutive cycles is considered an irregular cycle), total number of antral follicles (2-10 mm) in both ovaries (AFC) measured by a transvaginal scan and serum AMH (ng/ml), oestradiol, progesterone, FSH and LH.

Patients will return every two days to the clinic for a transvaginal ultrasound from stimulation day 5 up to and including the day of hCG. Serum hormone concentrations (FSH, LH, oestradiol, progesterone and AMH) will be measured on stimulation days 5 and 8 and on the day of hCG.

All hormones reported above will be measured in the central lab of the ospital as per routine practice. Remaining serum will be used for the AMH assay. The measurement of the AMH will ber profrmed in the ObGyn University research Lab.

Conditions

Infertility, Female

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Infertile women

the group consists of 80 infertile patients undergoing IVF

Corifollitropin alfa

Intervention Type: DRUG

AMH will be measured during ovarian stimulation with corifollitropin alfa

Interventions

Corifollitropin alfa

AMH will be measured during ovarian stimulation with corifollitropin alfa

Intervention Type: DRUG

Other Intervention Names

no other interventions

Eligibility Criteria

Inclusion Criteria

• basal serum FSH concentration below 20 UI/L
• age between 18 and 46 years
• body weight > 60 kg
• use of corifollitrofin alpha for ovarian stimulation.

Exclusion Criteria

• contraindications to IVF
• irregular menstrual cycles

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 46 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Azienda Ospedaliero-Universitaria di Modena

OTHER

Sponsor Role: lead

Responsible Party

Antonio La Marca

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Antonio La Marca

Role: PRINCIPAL_INVESTIGATOR

University of Modena and Reggio Emilia

Locations

Policlinico di Modena

Modena, Modena - MO, Italy

Site Status: RECRUITING

Countries

Italy

Central Contacts

Antonio La Marca

Role: CONTACT

antlamarca@libero.it

+390594224671

Antonio La Marca

Role: CONTACT

antlamarca@libero.it

3384795303

Facility Contacts

Antonio La Marca

Role: primary

antlamarca@libero.it

3384795303

Other Identifiers

184/2020

Identifier Type: -

Identifier Source: org_study_id